Target practice: Figuring out which, when, and why to use systemic therapies for metastatic colon cancer

Cancer Investigation

Volumn 24, Issue 1, 2006, Pages 98-105

  Holen, Kyle D ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Chemotherapy; Colon cancer; Fluorouracil; Irinotecan; Oxaliplatin; Review

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALPHA INTERFERON; ANTIBODY; BEVACIZUMAB; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DNA; DNA TOPOISOMERASE; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; HYBRID PROTEIN; IRINOTECAN; METHOTREXATE; NEUTRALIZING ANTIBODY; OXALIPLATIN; THYMIDYLATE SYNTHASE; VASCULOTROPIN;

ANGIOGENESIS; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CARCINOMA; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG HALF LIFE; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EPISTAXIS; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; MEDICAL PRACTICE; META ANALYSIS; METASTASIS; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; THROMBOEMBOLISM; TIME; TOXICITY; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLONIC NEOPLASMS; DNA; DNA TOPOISOMERASES, TYPE I; FLUOROURACIL; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYMIDYLATE SYNTHASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 32644489468     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500449637     Document Type: Review

References (59)

1. Doroshow, J.H.; Multhauf, P.; Leong, L.; et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously un-exposed to chemotherapy. J. Clin. Oncol. 1990, 8, 491-501.
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol. 1992, 10, 896-903.
3. Poon, M.A.; O'Connell, M.; Wieand, H.S.; et al. Biochemical modulation of fluorouracil with leucovorin. confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol. 1991, 9, 1967-1972.
4. Buroker, T.R.; O'Connell, M.J.; Wieand, H.D.; et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J. Clin. Oncol. 1994, 12, 14-20.
5. Leischman, C.G.; Fleming, T.R.; Muggia, F.M.; et al. Phase II study of fluorouracil and its modulation in advanced colorectal carcinoma: a prospective Southwest Oncology Group Study. J. Clin. Oncol. 1995, 13, 1303-1311.
6. Petrelli, N.; Douglas, H.O.; Herrera, L.; et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J. Clin. Oncol. 1989, 7, 1419-1426.
7. Sobrero, A.F.; Aschele, C.; Bertino, J.R. Fluorouracil in colorectal cancer: a tale of two drugs - Implications for biochemical modulation. J. Clin. Oncol. 1997, 15, 368-381.
8. Ardalan, B.; Chua, C.L.; Tian, E.; et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J. Clin. Oncol. 1991, 9, 625-630.
9. Kohne, C.H.; Schoffski, P.; Wilke, H.; et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J. Clin. Oncol. 1998, 16, 418-426.
10. De Gramont, A.; Bosset, J.F.; Milan, C.; et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J. Clin. Oncol. 1997, 15, 808-815.
11. Leichman, C.G.; Fleming, T.R.; Muggia, F.M.; et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J. Clin. Oncol. 1995, 13, 1303-1311.
12. Kohne, C.-H.; Wils, J.; Lorenz, M.; et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: european organization of research and treatment of cancer gastrointestinal group study 40952. J. Clin. Oncol. 2003, 21, 3721-3728.
13. Schuller, J.; Cassidy, J.; Reigner, B.G.; et al. Tumor selectivity of Xeloda in colorectal cancer patients. Cancer Chemother. Pharmacol. 2000, 45, 291-297.
14. Van Cutsem, E.; Twelves, C.; Cassidy, J.; et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J. Clin. Oncol. 2001, 19, 4097-4106.
15. Hoff, P.M.; Ansari, R.; Batist, G.; et al. Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: results of a Randomized Phase III Study. J. Clin. Oncol. 2001, 19, 2282-2292.
16. Kunimoto, T.; Nitta, K.; Kanaka, T.; et al. Antitumor activity of 7-ethyl-10 [4-(1-piperidino)-1-piperidino]-1-carbonyloxy-campotothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res. 1987, 47, 5944-5947.
17. Sakata, Y.; Nakao, I.; Futatsuki, K.; et al. Phase II study of CPT-11, a new camptothecin derivative, in patients with advanced gastrointestinal cancer. J. Jpn. Soc. Cancer Ther. 1992, 27, 2028-2035.
18. Shimada, Y.; Yoshino, M.; Wakui, A.; et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol. 1993, 11, 909-913.
19. Rothenberg, M.L.; Kuhn, J.G.; Burris, H.A.; et al. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 1993, 11, 2194-2204.
20. Rougier, P.; Bugat, R.; Douillard, J.Y.; et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin. Oncol. 1997, 15, 251-260.
21. Cunningham, D.; Pyrhonen, S.; James, R.; et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352, 1413-1418.
22. Rougier, P.; Van Cutsem, E.; Bajetta, E.; et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352, 1407-14121.
23. Conti, J.A.; Kemeny, N.E.; Saltz, L.B.; et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol. 1996, 14, 709-715.
24. Saltz, L.B.; Kanowitz, J.; Kemeny, N.; et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J. Clin. Oncol. 1996, 14, 2959-2967.
25. Vanhoefer, U.; Harstrick, A.; Kohne, C.; et al. Phase I study of weekly schedule of irinotecan, high-dose leucovorin, and infusion flourouracil as first-line chemotherapy in patients with advanced colorectal cancer. J. Clin. Oncol. 1999, 17, 907-913.
26. Douillard, J.Y.; Cunningham, D.; Roth, A.D.; et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000, 355, 1041-1047.
27. Saltz, L.; Cox, J.; Blanke, C.; et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Eng. J. Med. 2000, 343, 905-914.
28. Saltz, L.; Douillard, J.; Pirotta, N.; et al. Proc. Am. Soc. Clin. Oncol. 2000, 19, 938a [Abstract].
29. Fichtinger-Schepman, A.M.; Baan, R.A.; Luiten-Schuite, A.; et al. Immunochemical quantitation of adducts induced in DNA by cis- diamminedichloroplatinum (II) and analysis of adduct-related DNA unwinding. Chem. Biol. Interact. 1985, 55, 275-288.
30. Woynarowski, J.M.; Chapman, W.G.; Napier, C.; et al. Sequence and region specificity of oxaliplatin adducts in naked and cellular DNA. Mol. Pharmacol. 1998, 54, 770-777.
31. Diasio RB. Pharmacology of novel platinum analogues with activity in colorectal cancer. Advances in Colon Cancer 2003, 7 (2), 3-5.
32. Extra, J.M.; Espie, M.; Calvo, F.; et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemotherapy & Pharmacology 1990, 25 (4), 299-303.
33. Caussanel, J.P.; Levi, F.; Brienza, S.; et al. Phase I trial of 5-day continuous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. of the NCI 1990, 82 (12), 1046-1050.
34. Machover, D.; Dias-Rubio, E.; de Gramont, A.; et al. Two consecutive phase II studies of oxaliplatin (L-OH P) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Annals Oncol. 1996, 7 (1), 95-98.
35. Levi, F.; Perpoint, B.; Garufi, C.; et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Euro. J. Cancer 1993, 29A, 1280-1284.
36. Rothenberg, M.L.; Oza, A.M.; Bigelow, R.H.; et al. Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: interim Results of a Phase III Trial. J. Clin. Oncol. 2003, 21, 2059-2069.
37. Levi, F.; Misset, J.L.; Brienza, S.; et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992, 69, 893-900.
38. Bertheault-Cvitkovic, F.; Jami, A.; Ithzaki, M.; et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol. 1996, 14, 2950-2958.
39. De Gramont, A.; Vignoud, J.; Tournigand, C.; et al. Oxaliplatin with high-dose leucovorin and 5-flourouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Euro. J. Cancer 1997, 33 (2), 214-219.
40. De Gramont, A.; Figer, A.; Seymour, M.; et al. Leucovorin and flourouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18, 2938-2947.
41. Giacchetti, S.; Perpoint, B.; Zidani, R.; et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated flourouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Onc. 2000, 18, 136-147.
42. Maindrault-Goebel, F.; Louvet, C.; Andre, T.; et al. Oxaliplatin Added to the Simplifed Bimonthly Leucovorin and 5-Fluorouracil Regimen as Second-line Therapy for Metastatic Colorectal Cancer (FOLFOX6). Eur. J. Cancer 1999, 35 (9), 1338-1342.
43. Andre, T.; Figer, A.; Cervantes, A.; et al. FOLFOX7 compared to FOLFOX4: preliminary results of the randomized OPTIMOX study. Proc. ASCO 2003, 22, 253 (Abstract 1016).
44. Saltz, L.; Hochster, H.; Rubin, M.; et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. 2001, 20, 3a (Abstr 7).
45. Cunningham, D.; Humblet Y.; Siena S.; et al. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. N. Engl. J. Med. 2004, 351, 337-345, Jul 22, 2004.
46. Saltz, Leonard B.; Neal, Meropol J.; Loehrer, Patrick, J. Sr; et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 1201-1208.
47. Fan, Z.; Baselga, J.; Masui, H.; Mendelsohn, J.; et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cisdiaminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993, 53, 4637-4642.
48. Baselga, J.; Pfisher, D.; Cooper, M.R.; et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 2000, 18, 904-914.
49. Ciardiello, F.; Bianco, R.; Damiano, V.; et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 1999, 5, 909-916.
50. Tabernero, J.M.; Van Cutsem, E.; Sastre, J.; et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. Proc. Am. Soc. Clin. Oncol. 2004, 23, 248 (Abstr 3512).
51. Reinmuth, N.; Parikh, A.A.; Ahmad, S.A.; et al. Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech. 2003, 60, 199-207.
52. Kabbinavar, F.; Hurwitz, H.; Fehrenbacher, L.; et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003, 21, 60-65.
53. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
54. Benson, A.B.; Catalano, P.J.; Meropol, N.J.; O'Dwyer, P.J.; Giantonio, B.J. Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc. Am. Soc. Clin. Oncol. 2003, 22, 243 (Abstr 975).
55. Goldberg, Richard M.; Sargent, Daniel J.; Morton, Roscoe F.; et al. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. J. Clin. Oncol. 2004, 22, 23-30.
56. Tournigand, C.; Andre, T.; Achille, E.; et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004, 22, 229-237.
57. Cassidy, J.; Tabernero, J.; Twelves, C.; et al. XELOX (Capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol. 2004, 22, 2084-2091.
58. Saltz, L.B.; Lenz, H.; Kindler, H.; et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. 2005 Gastrointestinal Cancers Symposium Abstract #169b.
59. Chen, H.X.; Mooney, M.; Boron, M.; et al. Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: an NCI Treatment Referral Center trial (TRC-0301). Proc. Am. Soc. Clin. Oncol. 2004, 23, 249 (Abstr 3515).